Core Viewpoint - CAR-T cell therapy has shown strong therapeutic effects in B-cell malignancies, but for T-cell malignancies, genetic engineering modifications are necessary to prevent "self-destruction" of CAR-T cells [2]. Group 1: Research Development - A study published on February 2, 2026, by a team from Huazhong University of Science and Technology developed a CD5 knockout CAR-T cell therapy (CT125A) targeting CD5 in relapsed/refractory CD5+ hematological malignancies, demonstrating good efficacy and controllable safety in a Phase 1 clinical trial [2]. - CD5 is a scavenger receptor involved in regulating immune responses, primarily expressed in thymocytes, T cells, and a small subset of B cells, and is widely expressed in hematological malignancies, particularly in 85% of T-cell malignancies [4]. Group 2: Clinical Trial Results - In a Phase 1 clinical trial (NCT04767308) involving 7 patients with relapsed/refractory CD5+ hematological malignancies, CT125A achieved an overall response rate of 85.7% (6 out of 7 patients), including 4 complete responses [7]. - Safety assessments revealed that all patients experienced cytokine release syndrome, with 6 cases classified as grade 1-2 and 1 case as grade 3, alongside other adverse events such as cytopenia and infections [7][9]. Group 3: Implications and Future Considerations - The results indicate that CT125A has therapeutic potential in CD5+ malignancies, while also highlighting the need for safety optimization in clinical applications [9].